No specific studies have disclosed the role of NRF2 in cancer development in people with DS, however, the overexpression of BACH1, associated with the mitigation of NRF2 induction and the pro-apoptotic phenotype, might address the reduced risk of developing solid tumors. This evidence concerns the gene BACH1 and Dravet syndrome.